No Data
No Data
CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 77% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, CSPC Pharmaceutical Group fair value estimate is HK$10.93 Current share price of HK$6.18 suggests CSPC Pharmaceutical Group is potentially 43
CSPC Pharmaceutical Group's Respiratory Vaccine Gets NMPA's Nod for Clinical Trials
CSPC Pharmaceutical Group (HKG:1093) said China's National Medical Products Administration (NMPA) approved its mRNA Respiratory Syncytial Virus Vaccine for clinical trials.
Changjiang Securities: The vitamins D3 market is good and the business outlook is positive.
Vitamin D3 is a minor variety in the vitamins industry, mainly used in the field of fodder. With the gradual digestion of overseas market inventory and the steady recovery of domestic demand, the product demand side has been catalyzed marginally. As a high-quality industry with highly concentrated supply of raw materials, the leading players have a greater say and prices have greater elasticity.
CSPC Pharma (01093.HK): Respiratory syncytial virus mRNA vaccine (SYS6016) receives clinical trial approval.
On July 11th, Gelonhui reported that CSPC Pharma (01093.HK) announced that the respiratory syncytial virus (RSV) mRNA vaccine (SYS6016) developed by the group has obtained approval from the China National Medical Products Administration and can conduct clinical trials in China. According to the disclosure, the product is composed of a lipid nanoparticle that packages mRNA molecules encoding the pre-fusion conformation of the full-length fusion glycoprotein (F protein) of respiratory syncytial virus. It is suitable for preventing lower respiratory tract diseases caused by RSV infections. Preclinical studies have shown that the product is translated into pre-fusion conformation F protein in the body and induces ...
Express News | CSPC Pharmaceutical - Mrna Rsv Vaccine Obtains Clinical Trial Approval From Nmpa
CSPC Pharma (01093.HK) cancelled 36.35 million shares from repurchasing its own stock on July 11.
CSPC Pharma (01093.HK) announced that it will cancel 36.35 million repurchased shares on July 11, 2024.
No Data